Health tech companies – especially digital therapeutics ones – have had a tough time working with pharma companies. Among tech vendors, Aetion is an exception in that category. It has developed a Real-World Evidence (RWE) platform being used by Sanofi and other pharma companies.
As Covid-19 hit, the New York company entered into a research collaboration with the Food and Drug Administration to facilitate the understanding of what treatments are more effective in countering the SARS-CoV-2 virus that has claimed the lives of so many around the world.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In this episode of the MedCity pivot podcast, Aetion’s CEO, Carolyn Magill, talks about the importance of RWE and how it is being used in new drug applications and in negotiating value-based contracts. Here’s the full episode:
